Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3).
Okada M, Kato K, Cho BC, Takahashi M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Matsumura Y, Takazawa A, Kitagawa Y.
Okada M, et al. Among authors: kato k.
Clin Cancer Res. 2022 Aug 2;28(15):3277-3286. doi: 10.1158/1078-0432.CCR-21-0985.
Clin Cancer Res. 2022.
PMID: 35294546
Free PMC article.